Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovative assay for microRNAs analysis

Project description

An enhanced diagnostic tool identifying numerous diseases will soon be more accessible

DNA and RNA are so well-known they have practically become the topic of cocktail conversation. The new kids on the block are microRNAs (miRNAs). Since their serendipitous discovery in the early 1990s, there are now over 2 000 known miRNAs in humans believed to regulate about a third of the genes in the genome. These small pieces of RNA, about 25 nucleotides in length, regulate critical cellular functions including development, differentiation, growth and metabolism. Conditions as diverse as cancer, liver disease and age-related conditions have all been linked to miRNA function gone awry. LIVELMIA is developing a plan to get its miRNA analysis technology to market. Faster and cheaper diagnostic technology will encourage widespread uptake in clinics and hospitals globally.

Objective

MicroRNAs (miRNAs) are a class of newly discovered biomolecules implicated in numerous biological systems and in common human diseases (e.g. cancer, Alzheimer, osteoarthritis). It has been shown that MiRNAs are biomarkers with great diagnostic and prognostic value. MiRNAs can be the next generation targets for diagnostics and therapeutics and this is reflected in the miRNA analysis market which is forecasted to have a CAGR of 23.4% in the coming years. Unfortunately, miRNAs are very difficult to detect and measure. The methods we have today are complex, expensive and time consuming. These limitations are restricting the use of miRNA in clinics and hospitals for diagnostic medicine.
LIVELMIA is an answer to these problems. We has succeeded in developing a disruptive innovative method for high-throughput miRNAs analyses, that allows a general improvement in terms of cost, easy-of-use and accuracy. We have cut down the time required by nearly a factor of 2, bringing the total analysis time down from 6 hours to 3 hours. Furthermore LIVELMIA has a high specificity making it ideal in diagnostics to ensure quality readings in any condition. LIVELMIA is a chemical assay kit for quantification of miRNAs on various types of samples (blood, biopsies, cells) with applications in the field of health research and diagnostics medicine. Our ultimate goal is helping biomedical researchers to improve miRNA studies and move miRNA analysis from laboratory to the clinic to bring profound benefits to public health.
Today we have a TRL6/7 prototype. We are gaining considerable interest from potential customers, dealers and stakeholders. We have filed for a patent in 2018 and we are now submitting this Phase 1 proposal in order to study the feasibility and develop a business plan for LIVELMIA, where we intend to study the best segments for exploitation, our pricing strategy, costs, etc.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

BIORIDIS SRL
Net EU contribution
€ 50 000,00
Address
VIA ALFONSO RUBBIANI 5
40124 Bologna
Italy
SME
Yes
Region
Nord-Est Emilia-Romagna Bologna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00